1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(1-phenyl-3-(1-(trifluoromethyl)cyclopropyl)-1H-pyrazol-5-yl)urea | 1188908-88-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(1-phenyl-3-(1-(trifluoromethyl)cyclopropyl)-1H-pyrazol-5-yl)urea
• 英文别名: 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[2-phenyl-5-[1-(trifluoromethyl)cyclopropyl]pyrazol-3-yl]urea
• CAS: 1188908-88-4
• 化学式: C₃₀H₂₅F₃N₆O₄
• 分子量: 590.562
• InChiKey: PMQREKDSRVSUMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  43
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  phenyl 1-phenyl-3-(1-(trifluoromethyl)cyclopropyl)-1H-pyrazol-5-ylcarbamate 、 、 3-((6,7-dimethoxyquinazolin-4-yl)oxy)aniline 、 在 crude product 、 EtOAc hexanes 作用下， 以to give 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(1-phenyl-3-(1-(trifluoromethyl)cyclopropyl)-1H-pyrazol-5-yl)urea (139 mg, 0.24 mmol, 71%)的产率得到1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(1-phenyl-3-(1-(trifluoromethyl)cyclopropyl)-1H-pyrazol-5-yl)urea
  参考文献：
  名称：

  RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF

  摘要：

  提供了化合物、组合物和方法，用于调节RAF激酶的活性，包括BRAF激酶，并用于治疗、预防或改善由RAF激酶介导的一种或多种疾病或障碍的症状。

  公开号：

  US20160199375A1

文献信息

• RAF kinase modulator compounds and methods of use thereof
  申请人：Ambit Biosciences Corporation

  公开号：US08969587B2

  公开（公告）日：2015-03-03

  Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases.

  本发明提供了用于调节RAF激酶活性的化合物、组合物和方法，包括BRAF激酶，并用于治疗、预防或改善由RAF激酶介导的一种或多种疾病或障碍的症状。
• 1-(3-(6,7-DIMETHOXYQUINAZOLIN-4-YLOXY)PHENYL)-3-(5-(1,1,1-TRIFLUORO-2-METHYLPROPAN-2-YL)ISOXAZOL-3-YL)UREA AS RAF KINASE MODULATOR IN THE TREATMENT OF CANCER DISEASES
  申请人：Ambit Biosciences Corporation

  公开号：EP2947072A1

  公开（公告）日：2015-11-25

  Compounds, compositions and methods are provided for modulating the activity of RAF kinases, including BRAF kinase and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by RAF kinases. The compound is 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea, having the structure or a pharmaceutically acceptable salt, solvate, clathrate or hydrate thereof.

  本发明提供了用于调节 RAF 激酶（包括 BRAF 激酶）活性以及治疗、预防或改善由 RAF 激酶介导的疾病或紊乱的一种或多种症状的化合物、组合物和方法。 该化合物为 1-(3-(6,7-二甲氧基喹唑啉-4-氧基)苯基)-3-(5-(1,1,1-三氟-2-甲基丙-2-基)异恶唑-3-基)脲，其结构为 或其药学上可接受的盐、溶液、凝胶或水合物。
• QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF
  申请人：Ambit Biosciences Corporation

  公开号：EP2268623B1

  公开（公告）日：2015-05-06
• METHODS FOR TREATING HCV INFECTION
  申请人：Inhibikase Therpeutics, Inc.

  公开号：US20160101106A1

  公开（公告）日：2016-04-14

  The present invention provides methods of treating HCV infection in subjects (e.g., mammals), comprising administering to a subject in need thereof an effective amount of a RAF kinase inhibitor or a prodrug thereof. The present invention also provides methods of treating HCV infection, comprising administering to a subject in need thereof an effective amount of a RAF kinase inhibitor conjointly with at least one additional therapeutic agent (e.g., an antiviral agent).
• US8618289B2
  申请人：——

  公开号：US8618289B2

  公开（公告）日：2013-12-31